Guardant Health (NASDAQ:GH – Get Free Report) is expected to be posting its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to announce earnings of ($0.41) per share and revenue of $314.23 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.
Guardant Health Stock Down 1.3%
NASDAQ GH opened at $145.47 on Tuesday. Guardant Health has a fifty-two week low of $40.35 and a fifty-two week high of $174.08. The business has a fifty day moving average of $140.40 and a 200-day moving average of $112.25. The stock has a market cap of $19.29 billion, a price-to-earnings ratio of -42.91 and a beta of 1.59.
Wall Street Analysts Forecast Growth
A number of analysts recently commented on the company. JPMorgan Chase & Co. lifted their price objective on Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. BTIG Research raised their price target on shares of Guardant Health from $160.00 to $190.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Wolfe Research assumed coverage on shares of Guardant Health in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 price target on the stock. Canaccord Genuity Group lifted their price target on shares of Guardant Health from $135.00 to $205.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Finally, UBS Group set a $150.00 price objective on shares of Guardant Health in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $160.04.
Insiders Place Their Bets
In related news, Director Musa Tariq sold 1,951 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $131.16, for a total value of $255,893.16. Following the completion of the transaction, the director directly owned 11,048 shares in the company, valued at approximately $1,449,055.68. This represents a 15.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Brian Bell sold 2,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $128.62, for a total value of $257,240.00. Following the completion of the sale, the chief financial officer directly owned 47,509 shares in the company, valued at approximately $6,110,607.58. The trade was a 4.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 708,565 shares of company stock valued at $90,556,597. 5.60% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Guardant Health
Several hedge funds have recently modified their holdings of the stock. Mercer Global Advisors Inc. ADV increased its position in Guardant Health by 12.7% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 4,357 shares of the company’s stock worth $445,000 after purchasing an additional 490 shares during the last quarter. Mackenzie Financial Corp boosted its holdings in shares of Guardant Health by 57.6% in the 4th quarter. Mackenzie Financial Corp now owns 36,023 shares of the company’s stock valued at $3,617,000 after purchasing an additional 13,172 shares during the last quarter. Fuller & Thaler Asset Management Inc. grew its stake in shares of Guardant Health by 3.0% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock valued at $249,398,000 after buying an additional 72,162 shares during the period. XTX Topco Ltd grew its stake in shares of Guardant Health by 568.0% during the 4th quarter. XTX Topco Ltd now owns 23,695 shares of the company’s stock valued at $2,420,000 after buying an additional 20,148 shares during the period. Finally, Voloridge Investment Management LLC acquired a new stake in shares of Guardant Health during the 4th quarter worth $10,130,000. 92.60% of the stock is owned by institutional investors and hedge funds.
About Guardant Health
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Featured Stories
- Five stocks we like better than Guardant Health
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
